Liposomal Irinotecan and Apatinib in ES-SCLC

Recruiting now · Phase 2

Conditions studied: Small Cell Lung Cancer Extensive Stage

In brief

The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.

Key facts

Study ID

NCT06749691

Run by

Second Affiliated Hospital, Zhejiang University, School of Medicine

People needed

30

Starts

2024-12-28

Expected to finish

2027-12-01

Last updated by the study team

2024-12-27

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age range of 18-75 years;
• Expected survival period ≥ 12 weeks;
• At least one measurable lesion (according to RECIST V 1.1);
• For patients who have failed first-line or second-line treatment.

You may not qualify if…

• Have received any systemic treatment targeting VEGF or VEGFR in the past, such as treatment with anti angiogenic drugs such as ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, sorafenib.
• Active or uncontrolled severe infection (CTCAE 5.0 ≥ 2) and/or antibiotic treatment within 2 weeks prior to enrollment;
• There are multiple factors that affect the absorption of oral medication, such as inability to swallow, nausea and vomiting, chronic diarrhea, and intestinal obstruction;
• Those deemed unsuitable for inclusion by doctors;

Where it is running

• Second Affiliated Hospital of Zhejiang University — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.